Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36


Hyperpolarized helium-3 magnetic resonance lung imaging of non-sedated infants and young children: a proof-of-concept study.

Altes TA, Meyer CH, Mata JF, Froh DK, Paget-Brown A, Gerald Teague W, Fain SB, de Lange EE, Ruppert K, Botfield MC, Johnson MA, Mugler JP 3rd.

Clin Imaging. 2017 Sep - Oct;45:105-110. doi: 10.1016/j.clinimag.2017.04.004. Epub 2017 May 10.


Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis.

Altes TA, Johnson M, Fidler M, Botfield M, Tustison NJ, Leiva-Salinas C, de Lange EE, Froh D, Mugler JP 3rd.

J Cyst Fibros. 2017 Mar;16(2):267-274. doi: 10.1016/j.jcf.2016.12.004. Epub 2017 Jan 26.


Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.

Bove R, White CC, Giovannoni G, Glanz B, Golubchikov V, Hujol J, Jennings C, Langdon D, Lee M, Legedza A, Paskavitz J, Prasad S, Richert J, Robbins A, Roberts S, Weiner H, Ramachandran R, Botfield M, De Jager PL.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e162. doi: 10.1212/NXI.0000000000000162. eCollection 2015 Dec.


A signature for immune response correlates with HCV treatment outcome in Caucasian subjects.

Hare BJ, Haseltine E, Fleming M, Chelsky D, McIntosh L, Allard R, Botfield M.

Data Brief. 2015 Feb 11;3:56-61. doi: 10.1016/j.dib.2015.01.009. eCollection 2015 Jun.


A signature for immune response correlates with HCV treatment outcome in Caucasian subjects.

Hare BJ, Haseltine E, Fleming M, Chelsky D, McIntosh L, Allard R, Botfield M.

J Proteomics. 2015 Feb 26;116:59-67. doi: 10.1016/j.jprot.2014.12.015. Epub 2015 Jan 8.


Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.

Zeremski M, Dimova RB, Benjamin S, Penney MS, Botfield MC, Talal AH.

J Infect Dis. 2015 Jun 1;211(11):1795-9. doi: 10.1093/infdis/jiu807. Epub 2014 Dec 15.


Assessment of repeatability of hyperpolarized gas MR ventilation functional imaging in cystic fibrosis.

O'Sullivan B, Couch M, Roche JP, Walvick R, Zheng S, Baker D, Johnson M, Botfield M, Albert MS.

Acad Radiol. 2014 Dec;21(12):1524-9. doi: 10.1016/j.acra.2014.07.008. Epub 2014 Aug 27.


Telaprevir-based treatment effects on hepatitis C virus in liver and blood.

Talal AH, Dimova RB, Zhang EZ, Jiang M, Penney MS, Sullivan JC, Botfield MC, Chakilam A, Sawant R, Cervini CM, Zeremski M, Jacobson IM, Kwong AD.

Hepatology. 2014 Dec;60(6):1826-37. doi: 10.1002/hep.27202. Epub 2014 Jul 31.


Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.

Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR, Focaccia R, Horban A, Pockros PJ, Van Heeswijk RP, De Meyer S, Luo D, Botfield M, Beumont M, Picchio G.

J Hepatol. 2013 May;58(5):883-9. doi: 10.1016/j.jhep.2012.12.023. Epub 2013 Jan 12.


Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.

de Bruijne J, Sullivan JC, Kieffer TL, Botfield M, Shames B, Schinkel J, Molenkamp R, Weegink C, Reesink H.

J Clin Virol. 2012 Feb;53(2):174-7. doi: 10.1016/j.jcv.2011.11.004. Epub 2011 Dec 3.


Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, OrdoƱez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.


Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance.

Gross CH, Parsons JD, Grossman TH, Charifson PS, Bellon S, Jernee J, Dwyer M, Chambers SP, Markland W, Botfield M, Raybuck SA.

Antimicrob Agents Chemother. 2003 Mar;47(3):1037-46.


Crystal structure of calcium-free human sorcin: a member of the penta-EF-hand protein family.

Xie X, Dwyer MD, Swenson L, Parker MH, Botfield MC.

Protein Sci. 2001 Dec;10(12):2419-25.


Selective inhibition of Src SH2 by a novel thiol-targeting tricarbonyl-modified inhibitor and mechanistic analysis by (1)H/(13)C NMR spectroscopy.

Sundaramoorthi R, Siedem C, Vu CB, Dalgarno DC, Laird EC, Botfield MC, Combs AB, Adams SE, Yuan RW, Weigele M, Narula SS.

Bioorg Med Chem Lett. 2001 Jul 9;11(13):1665-9.


An efficient synthesis of a 4'-phosphonodifluoromethyl-3'-formyl-phenylalanine containing SRC SH2 ligand.

Shakespeare WC, Bohacek RS, Narula SS, Azimioara MD, Yuan RW, Dalgarno DC, Madden L, Botfield MC, Holt DA.

Bioorg Med Chem Lett. 1999 Nov 1;9(21):3109-12.


Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70.

Vu CB, Corpuz EG, Merry TJ, Pradeepan SG, Bartlett C, Bohacek RS, Botfield MC, Eyermann CJ, Lynch BA, MacNeil IA, Ram MK, van Schravendijk MR, Violette S, Sawyer TK.

J Med Chem. 1999 Oct 7;42(20):4088-98.


Tandem SH2 domains confer high specificity in tyrosine kinase signaling.

Ottinger EA, Botfield MC, Shoelson SE.

J Biol Chem. 1998 Jan 9;273(2):729-35.


The construction of a cysteine-less melibiose carrier from E. coli.

Weissborn AC, Botfield MC, Kuroda M, Tsuchiya T, Wilson TH.

Biochim Biophys Acta. 1997 Oct 23;1329(2):237-44.


SH3 domains and drug design: ligands, structure, and biological function.

Dalgarno DC, Botfield MC, Rickles RJ.

Biopolymers. 1997;43(5):383-400. Review.


Phage display selection of ligand residues important for Src homology 3 domain binding specificity.

Rickles RJ, Botfield MC, Zhou XM, Henry PA, Brugge JS, Zoller MJ.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10909-13.


Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide.

Narula SS, Yuan RW, Adams SE, Green OM, Green J, Philips TB, Zydowsky LD, Botfield MC, Hatada M, Laird ER, et al.

Structure. 1995 Oct 15;3(10):1061-73.


Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal.

Ladbury JE, Lemmon MA, Zhou M, Green J, Botfield MC, Schlessinger J.

Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3199-203.


Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries.

Rickles RJ, Botfield MC, Weng Z, Taylor JA, Green OM, Brugge JS, Zoller MJ.

EMBO J. 1994 Dec 1;13(23):5598-604.


Solution structure of a POU-specific homeodomain: 3D-NMR studies of human B-cell transcription factor Oct-2.

Sivaraja M, Botfield MC, Mueller M, Jancso A, Weiss MA.

Biochemistry. 1994 Aug 23;33(33):9845-55.


An invariant asparagine in the POU-specific homeodomain regulates the specificity of the Oct-2 POU motif.

Botfield MC, Jancso A, Weiss MA.

Biochemistry. 1994 Jul 5;33(26):8113-21.


Biochemical characterization of the Oct-2 POU domain with implications for bipartite DNA recognition.

Botfield MC, Jancso A, Weiss MA.

Biochemistry. 1992 Jun 30;31(25):5841-8.


Membrane topology of the melibiose carrier of Escherichia coli.

Botfield MC, Naguchi K, Tsuchiya T, Wilson TH.

J Biol Chem. 1992 Jan 25;267(3):1818-22.


The melibiose carrier of Escherichia coli.

Botfield MC, Wilson DM, Wilson TH.

Res Microbiol. 1990 Mar-Apr;141(3):328-31. Review. No abstract available.


Carboxyl-terminal truncations of the melibiose carrier of Escherichia coli.

Botfield MC, Wilson TH.

J Biol Chem. 1989 Jul 15;264(20):11643-8.


Alanine transport by lobster hepatopancreatic cell suspensions.

Ahearn GA, Monckton EA, Henry AE, Botfield MC.

Am J Physiol. 1983 Feb;244(2):R150-62. No abstract available.


Supplemental Content

Loading ...
Support Center